Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Morphine
Drug ID BADD_D01498
Description Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.[A176050] Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.[L12114]
Indications and Usage For the relief and treatment of severe pain.
Marketing Status Prescription; Discontinued
ATC Code N02AA01
DrugBank ID DB00295
KEGG ID D08233
MeSH ID D009020
PubChem ID 5288826
TTD Drug ID D0WE3O
NDC Product Code 42799-217
Synonyms Morphine | Morphia | Morphine Chloride | Chloride, Morphine | Morphine Sulfate | Sulfate, Morphine | SDZ 202-250 | SDZ 202 250 | SDZ 202250 | SDZ202-250 | SDZ202 250 | SDZ202250 | Morphine Sulfate (2:1), Pentahydrate | MS Contin | Contin, MS | Oramorph SR | Duramorph | Morphine Sulfate (2:1), Anhydrous
Chemical Information
Molecular Formula C17H19NO3
CAS Registry Number 57-27-2
SMILES CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cardiac arrhythmiasMu-type opioid receptorP35372T477688383026; 1528399; 1654493; 8490741; 1279757; 7521466
Cardiac arrhythmiasMu-type opioid receptorP35372T4776825806604
HyperpathiaMu-type opioid receptorP35372T4776825806604
HyperpathiaMitogen-activated protein kinase 8P45983T4009725806604
HyperpathiaProtein kinase C alpha typeP17252T1280825806604
HyperpathiaMu-type opioid receptorP35372T477688383026; 1528399; 1654493; 8490741; 1279757; 7521466
HyperpathiaTranscription factor JunP05412T6908525806604
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypothalamic pituitary adrenal axis suppression05.03.04.0070.000469%Not Available
Language disorder19.19.01.006; 17.02.08.0150.000469%Not Available
Cardiovascular symptom24.03.02.025; 02.01.02.0150.000469%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.001345%
Anion gap13.02.01.0180.000122%Not Available
Anion gap abnormal13.02.01.0190.000122%Not Available
Apnoeic attack17.02.05.051; 22.02.01.0270.000703%Not Available
Biopsy bone marrow abnormal13.01.08.0030.000469%Not Available
Concomitant disease aggravated08.01.03.063--Not Available
Congenital nail disorder03.05.02.001; 23.02.05.0220.000469%Not Available
Congenital nystagmus17.02.02.014; 06.05.02.018; 03.10.01.0070.000469%Not Available
Grunting22.02.01.0300.000469%Not Available
Locked-in syndrome17.01.04.0190.000469%Not Available
Maternal drugs affecting foetus18.03.03.009; 12.03.03.0060.001640%Not Available
Neonatal respiratory distress syndrome22.11.02.010; 18.04.10.0030.000611%Not Available
Occupational dermatitis23.03.04.0380.002577%Not Available
Oxygen saturation abnormal13.02.01.0280.000469%Not Available
PCO2 increased13.02.01.0300.000469%Not Available
Pupil fixed17.02.11.008; 06.05.03.0120.000122%Not Available
Rectal perforation07.04.01.0040.000183%
Respiratory rate increased13.15.01.0040.000469%Not Available
Symptom masked08.01.03.0780.000489%Not Available
Systemic mastocytosis10.02.01.014; 01.05.01.0110.000183%Not Available
Terminal state08.01.03.0790.000183%Not Available
Arachnoid cyst17.18.05.001; 16.09.05.0010.000244%Not Available
Neonatal hypotension24.06.03.014; 18.04.07.0080.000183%Not Available
Acute chest syndrome24.03.08.006; 22.06.03.004; 01.04.02.0040.002812%Not Available
Pneumococcal sepsis11.02.06.0070.000183%Not Available
Palatal oedema07.05.04.0080.000937%Not Available
Biliary dilatation09.02.03.0040.002109%Not Available
The 20th Page    First    Pre   20 21    Next   Last    Total 21 Pages